ADCYAP1 and Huntington disease: Moreover, Solés-Tarrés and colleagues [236] utilized PACAP (pituitary adenylate cyclase-activating polypeptide) in the R6/1 mouse model of Huntington’s disease, which exhibited anti-apoptotic and neurotrophic benefits, resulting in enhanced motor functions and reduced caspase-3 activity.